The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Cell and Gene Therapy Manufacturing QC-Global Market Insights and Sales Trends 2025
Synopsis
The global Cell and Gene Therapy Manufacturing QC market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Cell and Gene Therapy Manufacturing QC in various end use industries. The expanding demands from the Precision Therapy and Biological Research, are propelling Cell and Gene Therapy Manufacturing QC market. Safety Testing, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Purity Testing segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cell and Gene Therapy Manufacturing QC, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cell and Gene Therapy Manufacturing QC market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cell and Gene Therapy Manufacturing QC market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cell and Gene Therapy Manufacturing QC sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cell and Gene Therapy Manufacturing QC covered in this report include Bio-Techne Corporation, BioMerieux SA, Catalent, Inc., Charles River Laboratories International Inc., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Intertek Group plc, Lonza Group AG and Merck KGaA, etc.
The global Cell and Gene Therapy Manufacturing QC market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bio-Techne Corporation
BioMerieux SA
Catalent, Inc.
Charles River Laboratories International Inc.
Eurofins Scientific SE
F. Hoffmann-La Roche Ltd
Intertek Group plc
Lonza Group AG
Merck KGaA
Sartorius AG
SGS S.A.
Sistemic Scotland Limited
Thermo Fisher Scientific Inc.
Vigene Biosciences, Inc.
WuXi AppTec
Global Cell and Gene Therapy Manufacturing QC market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cell and Gene Therapy Manufacturing QC market, Segment by Type:
Safety Testing
Purity Testing
Potency Testing
Identity Testing
Stability Testing
Global Cell and Gene Therapy Manufacturing QC market, by Application
Precision Therapy
Biological Research
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Cell and Gene Therapy Manufacturing QC companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Cell and Gene Therapy Manufacturing QC market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Cell and Gene Therapy Manufacturing QC in various end use industries. The expanding demands from the Precision Therapy and Biological Research, are propelling Cell and Gene Therapy Manufacturing QC market. Safety Testing, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Purity Testing segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cell and Gene Therapy Manufacturing QC, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cell and Gene Therapy Manufacturing QC market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cell and Gene Therapy Manufacturing QC market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cell and Gene Therapy Manufacturing QC sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cell and Gene Therapy Manufacturing QC covered in this report include Bio-Techne Corporation, BioMerieux SA, Catalent, Inc., Charles River Laboratories International Inc., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Intertek Group plc, Lonza Group AG and Merck KGaA, etc.
The global Cell and Gene Therapy Manufacturing QC market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bio-Techne Corporation
BioMerieux SA
Catalent, Inc.
Charles River Laboratories International Inc.
Eurofins Scientific SE
F. Hoffmann-La Roche Ltd
Intertek Group plc
Lonza Group AG
Merck KGaA
Sartorius AG
SGS S.A.
Sistemic Scotland Limited
Thermo Fisher Scientific Inc.
Vigene Biosciences, Inc.
WuXi AppTec
Global Cell and Gene Therapy Manufacturing QC market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cell and Gene Therapy Manufacturing QC market, Segment by Type:
Safety Testing
Purity Testing
Potency Testing
Identity Testing
Stability Testing
Global Cell and Gene Therapy Manufacturing QC market, by Application
Precision Therapy
Biological Research
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Cell and Gene Therapy Manufacturing QC companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Cell and Gene Therapy Manufacturing QC
1.1 Cell and Gene Therapy Manufacturing QC Market Overview
1.1.1 Cell and Gene Therapy Manufacturing QC Product Scope
1.1.2 Cell and Gene Therapy Manufacturing QC Market Status and Outlook
1.2 Global Cell and Gene Therapy Manufacturing QC Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Cell and Gene Therapy Manufacturing QC Market Size by Region (2018-2029)
1.4 Global Cell and Gene Therapy Manufacturing QC Historic Market Size by Region (2018-2023)
1.5 Global Cell and Gene Therapy Manufacturing QC Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Cell and Gene Therapy Manufacturing QC Market Size (2018-2029)
1.6.1 North America Cell and Gene Therapy Manufacturing QC Market Size (2018-2029)
1.6.2 Europe Cell and Gene Therapy Manufacturing QC Market Size (2018-2029)
1.6.3 Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Size (2018-2029)
1.6.4 Latin America Cell and Gene Therapy Manufacturing QC Market Size (2018-2029)
1.6.5 Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Size (2018-2029)
2 Cell and Gene Therapy Manufacturing QC Market by Type
2.1 Introduction
2.1.1 Safety Testing
2.1.2 Purity Testing
2.1.3 Potency Testing
2.1.4 Identity Testing
2.1.5 Stability Testing
2.2 Global Cell and Gene Therapy Manufacturing QC Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Cell and Gene Therapy Manufacturing QC Historic Market Size by Type (2018-2023)
2.2.2 Global Cell and Gene Therapy Manufacturing QC Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Cell and Gene Therapy Manufacturing QC Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Cell and Gene Therapy Manufacturing QC Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Cell and Gene Therapy Manufacturing QC Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Cell and Gene Therapy Manufacturing QC Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Cell and Gene Therapy Manufacturing QC Revenue Breakdown by Type (2018-2029)
3 Cell and Gene Therapy Manufacturing QC Market Overview by Application
3.1 Introduction
3.1.1 Precision Therapy
3.1.2 Biological Research
3.2 Global Cell and Gene Therapy Manufacturing QC Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Cell and Gene Therapy Manufacturing QC Historic Market Size by Application (2018-2023)
3.2.2 Global Cell and Gene Therapy Manufacturing QC Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Cell and Gene Therapy Manufacturing QC Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Cell and Gene Therapy Manufacturing QC Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Cell and Gene Therapy Manufacturing QC Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Cell and Gene Therapy Manufacturing QC Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Cell and Gene Therapy Manufacturing QC Revenue Breakdown by Application (2018-2029)
4 Cell and Gene Therapy Manufacturing QC Competition Analysis by Players
4.1 Global Cell and Gene Therapy Manufacturing QC Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cell and Gene Therapy Manufacturing QC as of 2022)
4.3 Date of Key Players Enter into Cell and Gene Therapy Manufacturing QC Market
4.4 Global Top Players Cell and Gene Therapy Manufacturing QC Headquarters and Area Served
4.5 Key Players Cell and Gene Therapy Manufacturing QC Product Solution and Service
4.6 Competitive Status
4.6.1 Cell and Gene Therapy Manufacturing QC Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Bio-Techne Corporation
5.1.1 Bio-Techne Corporation Profile
5.1.2 Bio-Techne Corporation Main Business
5.1.3 Bio-Techne Corporation Cell and Gene Therapy Manufacturing QC Products, Services and Solutions
5.1.4 Bio-Techne Corporation Cell and Gene Therapy Manufacturing QC Revenue (US$ Million) & (2018-2023)
5.1.5 Bio-Techne Corporation Recent Developments
5.2 BioMerieux SA
5.2.1 BioMerieux SA Profile
5.2.2 BioMerieux SA Main Business
5.2.3 BioMerieux SA Cell and Gene Therapy Manufacturing QC Products, Services and Solutions
5.2.4 BioMerieux SA Cell and Gene Therapy Manufacturing QC Revenue (US$ Million) & (2018-2023)
5.2.5 BioMerieux SA Recent Developments
5.3 Catalent, Inc.
5.3.1 Catalent, Inc. Profile
5.3.2 Catalent, Inc. Main Business
5.3.3 Catalent, Inc. Cell and Gene Therapy Manufacturing QC Products, Services and Solutions
5.3.4 Catalent, Inc. Cell and Gene Therapy Manufacturing QC Revenue (US$ Million) & (2018-2023)
5.3.5 Charles River Laboratories International Inc. Recent Developments
5.4 Charles River Laboratories International Inc.
5.4.1 Charles River Laboratories International Inc. Profile
5.4.2 Charles River Laboratories International Inc. Main Business
5.4.3 Charles River Laboratories International Inc. Cell and Gene Therapy Manufacturing QC Products, Services and Solutions
5.4.4 Charles River Laboratories International Inc. Cell and Gene Therapy Manufacturing QC Revenue (US$ Million) & (2018-2023)
5.4.5 Charles River Laboratories International Inc. Recent Developments
5.5 Eurofins Scientific SE
5.5.1 Eurofins Scientific SE Profile
5.5.2 Eurofins Scientific SE Main Business
5.5.3 Eurofins Scientific SE Cell and Gene Therapy Manufacturing QC Products, Services and Solutions
5.5.4 Eurofins Scientific SE Cell and Gene Therapy Manufacturing QC Revenue (US$ Million) & (2018-2023)
5.5.5 Eurofins Scientific SE Recent Developments
5.6 F. Hoffmann-La Roche Ltd
5.6.1 F. Hoffmann-La Roche Ltd Profile
5.6.2 F. Hoffmann-La Roche Ltd Main Business
5.6.3 F. Hoffmann-La Roche Ltd Cell and Gene Therapy Manufacturing QC Products, Services and Solutions
5.6.4 F. Hoffmann-La Roche Ltd Cell and Gene Therapy Manufacturing QC Revenue (US$ Million) & (2018-2023)
5.6.5 F. Hoffmann-La Roche Ltd Recent Developments
5.7 Intertek Group plc
5.7.1 Intertek Group plc Profile
5.7.2 Intertek Group plc Main Business
5.7.3 Intertek Group plc Cell and Gene Therapy Manufacturing QC Products, Services and Solutions
5.7.4 Intertek Group plc Cell and Gene Therapy Manufacturing QC Revenue (US$ Million) & (2018-2023)
5.7.5 Intertek Group plc Recent Developments
5.8 Lonza Group AG
5.8.1 Lonza Group AG Profile
5.8.2 Lonza Group AG Main Business
5.8.3 Lonza Group AG Cell and Gene Therapy Manufacturing QC Products, Services and Solutions
5.8.4 Lonza Group AG Cell and Gene Therapy Manufacturing QC Revenue (US$ Million) & (2018-2023)
5.8.5 Lonza Group AG Recent Developments
5.9 Merck KGaA
5.9.1 Merck KGaA Profile
5.9.2 Merck KGaA Main Business
5.9.3 Merck KGaA Cell and Gene Therapy Manufacturing QC Products, Services and Solutions
5.9.4 Merck KGaA Cell and Gene Therapy Manufacturing QC Revenue (US$ Million) & (2018-2023)
5.9.5 Merck KGaA Recent Developments
5.10 Sartorius AG
5.10.1 Sartorius AG Profile
5.10.2 Sartorius AG Main Business
5.10.3 Sartorius AG Cell and Gene Therapy Manufacturing QC Products, Services and Solutions
5.10.4 Sartorius AG Cell and Gene Therapy Manufacturing QC Revenue (US$ Million) & (2018-2023)
5.10.5 Sartorius AG Recent Developments
5.11 SGS S.A.
5.11.1 SGS S.A. Profile
5.11.2 SGS S.A. Main Business
5.11.3 SGS S.A. Cell and Gene Therapy Manufacturing QC Products, Services and Solutions
5.11.4 SGS S.A. Cell and Gene Therapy Manufacturing QC Revenue (US$ Million) & (2018-2023)
5.11.5 SGS S.A. Recent Developments
5.12 Sistemic Scotland Limited
5.12.1 Sistemic Scotland Limited Profile
5.12.2 Sistemic Scotland Limited Main Business
5.12.3 Sistemic Scotland Limited Cell and Gene Therapy Manufacturing QC Products, Services and Solutions
5.12.4 Sistemic Scotland Limited Cell and Gene Therapy Manufacturing QC Revenue (US$ Million) & (2018-2023)
5.12.5 Sistemic Scotland Limited Recent Developments
5.13 Thermo Fisher Scientific Inc.
5.13.1 Thermo Fisher Scientific Inc. Profile
5.13.2 Thermo Fisher Scientific Inc. Main Business
5.13.3 Thermo Fisher Scientific Inc. Cell and Gene Therapy Manufacturing QC Products, Services and Solutions
5.13.4 Thermo Fisher Scientific Inc. Cell and Gene Therapy Manufacturing QC Revenue (US$ Million) & (2018-2023)
5.13.5 Thermo Fisher Scientific Inc. Recent Developments
5.14 Vigene Biosciences, Inc.
5.14.1 Vigene Biosciences, Inc. Profile
5.14.2 Vigene Biosciences, Inc. Main Business
5.14.3 Vigene Biosciences, Inc. Cell and Gene Therapy Manufacturing QC Products, Services and Solutions
5.14.4 Vigene Biosciences, Inc. Cell and Gene Therapy Manufacturing QC Revenue (US$ Million) & (2018-2023)
5.14.5 Vigene Biosciences, Inc. Recent Developments
5.15 WuXi AppTec
5.15.1 WuXi AppTec Profile
5.15.2 WuXi AppTec Main Business
5.15.3 WuXi AppTec Cell and Gene Therapy Manufacturing QC Products, Services and Solutions
5.15.4 WuXi AppTec Cell and Gene Therapy Manufacturing QC Revenue (US$ Million) & (2018-2023)
5.15.5 WuXi AppTec Recent Developments
6 North America
6.1 North America Cell and Gene Therapy Manufacturing QC Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Cell and Gene Therapy Manufacturing QC Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Cell and Gene Therapy Manufacturing QC Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Cell and Gene Therapy Manufacturing QC Market Dynamics
11.1 Cell and Gene Therapy Manufacturing QC Industry Trends
11.2 Cell and Gene Therapy Manufacturing QC Market Drivers
11.3 Cell and Gene Therapy Manufacturing QC Market Challenges
11.4 Cell and Gene Therapy Manufacturing QC Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
